Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Percheron Therapeutics ( (AU:PER) ) has issued an announcement.
Percheron Therapeutics Limited announced the results of its General Meeting, where over 90% of shareholders voted to retain the current Board, rejecting nominees from Powerhouse Ventures Limited. This strong shareholder support allows the company to concentrate on its mission to restore value for shareholders and continue its focus on developing therapies for rare diseases.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for rare diseases. The company’s lead program, avicursen (ATL1102), is an antisense oligonucleotide targeting the CD49d receptor, investigated for inflammatory conditions like multiple sclerosis and Duchenne muscular dystrophy.
Technical Sentiment Signal: Sell
Current Market Cap: $7.6M
For an in-depth examination of PER stock, go to TipRanks’ Stock Analysis page.